Cepheid Beats On Robust Top Line
Cepheid (NASDAQ:CPHD) reported EPS of 3 cents during the third quarter of fiscal 2011, scraping a penny past the Zacks Consensus Estimate and much better than the loss of 2 cents in the year-ago period. Revenues during the quarter increased 25% to $70.2 million, beating the Zacks Consensus Estimate of $68 million. The upside was [...]
Cepheid (NASDAQ:CPHD) reported EPS of 3 cents during the third quarter of fiscal 2011, scraping a penny past the Zacks Consensus Estimate and much better than the loss of 2 cents in the year-ago period.
Revenues during the quarter increased 25% to $70.2 million, beating the Zacks Consensus Estimate of $68 million. The upside was driven by a 33% growth at the Clinical segment attributable to strong sales of reagents and systems. Cepheid’s higher bottom line owed much to revenue growth.
Among the … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards